Sounds simple
In July 2022, the FDAs Pharmacy Compounding Advisory Committee (PCAC) voted against inclusion of enclomiphene citrate on the final 503A bulks list, though the material remains listed as category 1 on the most recent iteration of the 503A bulk drugs list
Option 1: Discard and mix fresh Cost: Price of new vial Benefit: Guaranteed full potency Risk: None (besides cost) Option 2: Continue using Cost: None (already paid for) Benefit: Don't waste remaining peptide Risk: 10-15% potency loss means 10-15% less effectiveness Calculation: If vial costs $50 and you're at day 35 with half remaining, you're deciding whether to waste $25 to guarantee full potency, or accept 10-15% reduced effectiveness
Such important mechanisms, nonetheless, fail to fully account for the in vitro and in vivo immunologic actions of DMF (39)
Some plaintiffs allege that delayed digestion became so severe that the stomach could no longer properly process or prevent food from remaining in the digestive system for extended periods of time
Alkhezi OS, Alsuhaibani HA, Alhadyab AA, et al